Compare BioNTech SE - ADR (BNTX) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? BioNTech SE - ADR trades at $91.88 (market cap $22.86B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.4. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | VEA | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | — |
52-Week High | $119.34 | $72.39 |
52-Week Low | $83.89 | $56.02 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
VEA trades at $69.76, down 1.73% over the past day, with technical indicators signaling a bearish trend. The ETF offers broad exposure to developed international markets with a low expense ratio of 0.03% and a forward P/E of 17.7x, providing a valuation discount to US equities. Recent news highlights its outperformance versus US benchmarks and strong asset growth under Vanguard's management.
Outlook remains positive for long-term diversification given its cost efficiency and geographic reach, though near-term risks include central bank rate hikes and political uncertainty in key markets like the UK. The bearish technical setup suggests potential for further consolidation before resuming upward momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
